|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 years and older
|
|
gptkbp:allocates
|
non-randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 2
|
|
gptkbp:completedIn
|
August 2012
|
|
gptkbp:conditionStudied
|
metastatic melanoma
|
|
gptkbp:drugClass
|
gptkb:BRAF_inhibitor
|
|
gptkbp:eligibility
|
histologically confirmed metastatic melanoma with BRAF V600 mutation
|
|
gptkbp:enrollment
|
132
|
|
gptkbp:gender
|
all
|
|
gptkbp:intervention
|
gptkb:PLX4032
gptkb:RO5185426
|
|
gptkbp:location
|
gptkb:Australia
gptkb:France
gptkb:Germany
gptkb:Italy
gptkb:Netherlands
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:United_States
|
|
gptkbp:mask
|
none (open label)
|
|
gptkbp:otherIdentifier
|
2010-023957-13
|
|
gptkbp:purpose
|
gptkb:psychotherapy
|
|
gptkbp:recognizedBy
|
gptkb:NCT01327846
|
|
gptkbp:result
|
overall response rate
|
|
gptkbp:secondaryOutcome
|
overall survival
progression-free survival
duration of response
|
|
gptkbp:sponsor
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:startDate
|
April 2011
|
|
gptkbp:status
|
completed
|
|
gptkbp:studyType
|
interventional
|
|
gptkbp:title
|
gptkb:A_Study_of_RO5185426_(PLX4032)_in_Previously_Treated_Patients_With_Metastatic_Melanoma
|
|
gptkbp:bfsParent
|
gptkb:CANTOS_trial
|
|
gptkbp:bfsLayer
|
6
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
NCT01327846
|